Oncostatin M in the anti-inflammatory response.
Oncostatin M (OM) is a pleiotropic cytokine of the interleukin 6 family, whose in vivo properties and physiological function remain in dispute and poorly defined. These in vivo studies strongly suggest that OM is anabolic, promoting wound healing and bone formation, and anti-inflammatory. In models of inflammation OM is produced late in the cytokine response and protects from lipopolysaccharide (LPS)-induced toxicities, promoting the re-establishment of homoeostasis by cooperating with proinflammatory cytokines and acute phase molecules to alter and attenuate the inflammatory response. Administration of OM inhibited bacterial LPS-induced production of tumour necrosis factor alpha and septic lethality in a dose dependent manner. Consistent with these findings, in animal models of chronic inflammatory disease OM potently suppressed inflammation and tissue destruction in murine models of rheumatoid arthritis and multiple sclerosis. T cell function and antibody production were not impaired by OM treatment. Taken together, these data indicate that the activities of this cytokine in vivo are anti-inflammatory without concordant immunosuppression.
Wahl
A F
AF
Seattle Genetics, Inc, Bothell, WA 98021, USA. awahl@seagen.com
Wallace
P M
PM
D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy; D001424:Bacterial Infections / Q000378:metabolism; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology*; D008070:Lipopolysaccharides; D051379:Mice; D023421:Models, Animal; D009103:Multiple Sclerosis / Q000188:drug therapy; D053683:Oncostatin M; D010455:Peptides / Q000502:physiology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology
D018836:Inflammation Mediators; D008070:Lipopolysaccharides; C508351:OSM protein, human; C508352:Osm protein, mouse; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D053683:Oncostatin M